Related Experiment Video
Updated: Apr 4, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Anticancer molecule AS1411 exhibits low nanomolar antiviral activity against HIV-1
Mathieu Métifiot1, Samir Amrane2, Jean-Louis Mergny2
1Laboratoire MFP, CNRS UMR-5234, Université de Bordeaux, FR Transbiomed, 146 Rue Léo Saignat, 33076 Bordeaux, France.
Abstract:
During clinical trials, a number of fully characterized molecules are dropped along the way because they do not provide enough benefit for the patient. Some of them show limited side effects and might be of great use for other applications. AS1411 is a nucleolin-targeting aptamer that underwent phase II clinical trials as anticancer agent. Here, we show that AS1411 exhibits extremely potent antiviral activity and is therefore an attractive new lead as anti-HIV agent.
More Related Videos
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Retrovirus Life Cycles
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...

